吉非替尼治疗化疗失败的晚期非小细胞肺癌38例  

Gefitinib(ZD1839) in the Treatment of 38 Cases with Advanced Non-Small Cell Lung Cancer who Failed to Respond Previous Chemotherapy

作　　者：夏国豪[1] 史美祺[1] 江伟[1] 许林[1] 潘良熹[1] 冯继锋[1] 

机构地区：[1]江苏省肿瘤医院肿瘤内科,江苏南京210009

出　　处：《肿瘤基础与临床》2007年第5期390-392,共3页journal of basic and clinical oncology

基　　金：江苏省科技发展计划项目(编号:BS2006005)

摘　　要：目的 观察吉非替尼（gefitinib，ZD1839）治疗化疗失败的晚期非小细胞肺癌的疗效及毒副反应。方法 2003年4月至2006年6月用吉非替尼治疗化疗失败的晚期非小细胞肺癌38例，服药至疾病进展或出现不可耐受的毒副反应。结果 38例均可评价疗效，获得CR 0例，PR 8例（21.05%），SD 18例（47.37%），疾病控制率为68.42%，PD 12例（31.57%）；中位生存时间7个月（1～26个月），中位疾病进展时间4.5个月，与药物相关的毒副反应为：皮疹19例（50%）、恶心10例（26.3%）、腹泻9例（23.68%）、皮肤干燥5例（13.16%）、乏力3例（7.89%），其它如发热、口腔溃疡及关节痛等毒副反应发生率均〈5%，实验室指标末见明显异常。结论 吉非替尼治疗化疗失败的晚期非小细胞肺癌疗效好，毒副反应少，耐受性好，可提高患者生活质量，延长生存期。Objective To observe the efficacy and drug-related toxicity of gefitinib（ZD1839） in the treatment of the 38 cases with advanced non-small cell lung cancer who failed to respond previous chemotherapy. Methods Thirty-eight non-small cell lung cancer patients who failed to respond previous chemotherapy were treated from Apr. 2003 to Jun. 2006. Gefitinib was given as a single drug at a dose of 250 mg per day orally until disease progressed or unaceeptable toxicity occurred. Results Among these 38 patients, complete response 0 （0%） , partial response 8 （21.05%） , stable disease 18 （47.37%） , disease control rate 68.42% , progressive disease 12 （31.5＂7%）. Median survival time of the entire group was 7 months （ 1 - 26 months）. Median time to progression was 4.5 months. The drug-related adverse reactions are skin rash 19 （50%）, nausea 10 （26.3%）, diarrhea9 （23.68%）, xerosis curls5 （13. 16%）, fatigue3 （7.89%）. The rates of adverse reactions such as fever, dental ulcer and arthralgia were bellow 5%. The breadboard index is normal. Conclusions Gefitinib is an effective drug in the treatment of the cases with advanced non-small cell lung cancer who failed to respond previous chemotherapy. The toxicity can be well acceptable.

关 键 词：吉非替尼 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]